Axsome Therapeutics Valuation
| AXSM Stock | USD 98.68 0.49 0.50% |
At this time, the firm appears to be undervalued. Axsome Therapeutics shows a prevailing Real Value of $104.11 per share. The current price of the firm is $98.68. Our model approximates the value of Axsome Therapeutics from analyzing the firm fundamentals such as Profit Margin of (0.92) %, return on equity of -1.72, and Current Valuation of 4.65 B as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Axsome Therapeutics' valuation include:
Price Book 51.4787 | Enterprise Value 4.6 B | Enterprise Value Ebitda (14.81) | Price Sales 14.1296 | Enterprise Value Revenue 13.7306 |
Undervalued
Today
Please note that Axsome Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Axsome Therapeutics is based on 3 months time horizon. Increasing Axsome Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Axsome stock is determined by what a typical buyer is willing to pay for full or partial control of Axsome Therapeutics. Since Axsome Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Axsome Stock. However, Axsome Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 98.68 | Real 104.11 | Target 116.45 | Hype 98.47 | Naive 100.56 |
The intrinsic value of Axsome Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Axsome Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Axsome Therapeutics helps investors to forecast how Axsome stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Axsome Therapeutics more accurately as focusing exclusively on Axsome Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Axsome Therapeutics' intrinsic value based on its ongoing forecasts of Axsome Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Axsome Therapeutics' closest peers.
Axsome Therapeutics Cash |
|
Axsome Valuation Trend
Knowing Axsome Therapeutics' actual value is paramount for traders when making sound investment determinations. Using both Axsome Therapeutics' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Axsome Revenue by Product
Axsome Therapeutics Total Value Analysis
Axsome Therapeutics is presently projected to have valuation of 4.65 B with market capitalization of 4.78 B, debt of 186.37 M, and cash on hands of 73.39 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Axsome Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
4.65 B | 4.78 B | 186.37 M | 73.39 M |
Axsome Therapeutics Investor Information
About 17.0% of the company shares are held by company insiders. The company recorded a loss per share of 6.58. Axsome Therapeutics had not issued any dividends in recent years. Based on the key indicators related to Axsome Therapeutics' liquidity, profitability, solvency, and operating efficiency, Axsome Therapeutics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.Axsome Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Axsome Therapeutics has an asset utilization ratio of 46.0 percent. This suggests that the Company is making $0.46 for each dollar of assets. An increasing asset utilization means that Axsome Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Axsome Therapeutics Ownership Allocation
Axsome Therapeutics holds a total of 48.46 Million outstanding shares. The majority of Axsome Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Axsome Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Axsome Therapeutics. Please pay attention to any change in the institutional holdings of Axsome Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Axsome Therapeutics Profitability Analysis
The company reported the previous year's revenue of 270.6 M. Net Loss for the year was (239.24 M) with profit before overhead, payroll, taxes, and interest of 45.94 M.About Axsome Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Axsome Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Axsome Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Axsome Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Axsome Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Axsome Therapeutics. We calculate exposure to Axsome Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Axsome Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 244.5 M | 256.8 M | |
| Pretax Profit Margin | (0.88) | (0.92) | |
| Operating Profit Margin | (0.86) | (0.90) | |
| Net Loss | (0.88) | (0.93) | |
| Gross Profit Margin | 0.90 | 0.72 |
Axsome Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Axsome Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 45.4 M |
Axsome Therapeutics Current Valuation Indicators
Axsome Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Axsome Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Axsome Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Axsome Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Axsome Therapeutics' worth.When determining whether Axsome Therapeutics is a strong investment it is important to analyze Axsome Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Axsome Therapeutics' future performance. For an informed investment choice regarding Axsome Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.58) | Revenue Per Share 7.108 | Quarterly Revenue Growth 0.813 | Return On Assets (0.26) | Return On Equity (1.72) |
The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.